Study reveals alarming increase in Alzheimer’s among working-age Finns
A recent Finnish study reveals a concerning trend: Alzheimer’s disease is increasingly affecting working-age individuals. While there is currently no cure for the disease, medication can often help alleviate symptoms. The European Medicines Agency is now reviewing an approval request for a new treatment that could significantly slow the progression of Alzheimer’s. Approved for sale in the United States under the name Leqembi, this medication shows promise compared to existing treatments that primarily target symptoms without impacting the disease’s course.
Eino Solje, an associate professor at the University of Eastern Finland, noted in a morning news program that the new drug could help maintain patients’ functional abilities, allowing more individuals to enjoy fulfilling years, potentially even at home. Geriatrician Arvo Haapanen emphasized the transformative potential of this medication, marking a shift in treatment from merely addressing symptoms to actually hindering disease progression.
However, if approved in Europe, it may take about a year before the drug is available for patient use, as its benefits must outweigh potential risks. The medication carries side effects that necessitate careful consideration before prescription, including rare instances of brain swelling and bleeding.
The reasons behind the rising prevalence of Alzheimer’s among working-age individuals remain unclear, according to Solje, who led the research project. Over a 12-year follow-up, there was a marked increase in cases among this demographic, prompting an urgent need for investigation.
While Alzheimer’s remains rare in this age group, those concerned about memory issues should pay close attention. An estimated 2,700 working-age Finns are affected by cognitive disorders, and it is crucial for family and friends to recognize potential symptoms early.